Modified Cabrol shunt to treat left ventricular rupture.

Ann Thorac Surg

Department of Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, New York 10029, USA.

Published: January 2010

Left ventricular rupture is a rare but potentially fatal complication of mitral valve replacement. We describe how a modified Cabrol shunt was used to address intractable hemorrhage from a left ventricular rupture after reoperative mitral valve replacement.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2009.04.075DOI Listing

Publication Analysis

Top Keywords

left ventricular
12
ventricular rupture
12
modified cabrol
8
cabrol shunt
8
mitral valve
8
valve replacement
8
shunt treat
4
treat left
4
rupture left
4
rupture rare
4

Similar Publications

Background: Atrial fibrillation (AF) is the most prevalent arrhythmia encountered in clinical practice. Triglyceride glucose index (Tyg), a convenient evaluation variable for insulin resistance, has shown associations with adverse cardiovascular outcomes. However, studies on the Tyg index's predictive value for adverse prognosis in patients with AF without diabetes are lacking.

View Article and Find Full Text PDF

This study investigated the correlation between quantitative echocardiographic characteristics within 3 days of birth and necrotizing enterocolitis (NEC) and its severity in preterm infants. A retrospective study was conducted on 168 preterm infants with a gestational age of < 34 weeks. Patients were categorized into NEC and non-NEC groups.

View Article and Find Full Text PDF

Background: The benefit of mechanical circulatory support (MCS) with Impella (Abiomed, Inc, Danvers, MA) for patients undergoing non-emergent, high-risk percutaneous coronary intervention (HR-PCI) is unclear and currently the subject of a large randomized clinical trial (RCT), PROTECT IV. While contemporary registry data from PROTECT III demonstrated improvement of outcomes with Impella when compared with historical data (PROTECT II), there is lack of direct comparison to the HR-PCI cohort that did not receive Impella support.

Methods: We retrospectively identified patients from our institution meeting PROTECT III inclusion criteria (left ventricular ejection fraction [LVEF] <35% with unprotected left main or last remaining vessel or LVEF <30% undergoing multivessel PCI), and compared this group (NonIMP) to the published outcomes data from the PROTECT III registry (IMP).

View Article and Find Full Text PDF

Background: The assessment of left ventricular (LV) systolic function and quantification of LV ejection fraction (EF) in patients with atrial fibrillation (AF) can be difficult. We previously demonstrated that LV volume changes over the 100 ms of systole (LVEF) can be used as a measure of LV systolic function.

Objective: We sought to evaluate the applicability of LVEF in AF patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!